Professor Harry Iland, from Royal Prince Alfred Hospital in Sydney, told the HAA meeting how the treatment of acute promyelocytic leukaemia (APL) has evolved from non-selective ‘blunderbuss’ therapy anthracyclines through the addition of vitamin A-based retinoids and most recently, arsenic. Delivering the Carl de Gruchy Oration, Professor Iland explained how the cytogenetic and molecular abnormalities ...
Curing acute promyelocytic leukaemia: Blunderbuss, vitamins, and a poison chaser
By Tony James
17 Nov 2016